| |
| |
| Catalent Signs Agreement with AstraZeneca to Expand Manufacturing Support for COVID-19 Vaccine AZD1222 |
|
|
|
|
|
| Catalent will provide drug substance manufacturing to AstraZeneca for the University of Oxford’s adenovirus vector-based COVID-19 vaccine, AZD1222, at Catalent’s commercial gene therapy manufacturing facility located in Harmans, Maryland.
This agreement expands Catalent’s support of the AZD1222 program following the announcement in June that its facility in Anagni, Italy, will provide large-scale vial filling and packaging of AZD1222 |
|
|
| | |
|
|
| |
| |
| Catalent Gene Therapy Facility Receives FDA Approval as an Additional Manufacturing Site for AveXis’ Gene Therapy
Catalent is FDA approved to produce commercial drug substance intermediate for AveXis’ spinal muscular atrophy (SMA) gene therapy at its manufacturing facility located in Harmans. |
|
|
|
|
|
| |
| |
| Catalent is Proud to Support Many High-Profile Covid-19 Programs
Catalent is working with over 50 customers on multiple COVID-19-related antivirals, vaccines, diagnostics and treatments for symptoms and effects of virus. Find out more. |
|
|
|
|
|
| |
| |
| Bloomberg Visits Catalent’s Facility in Anagni, Italy
Mario Gargiulo, Region President, Catalent Biologics, recently escorted Bloomberg on a tour of Catalent’s Anagni facility to highlight the role the site will play in supporting a potential COVID vaccine. On the tour, he explained the vial filling and packaging processes at the state-of-the-art facility. |
|
|
|
|
|
| |
| |
| Catalent Adds Potent Manufacturing Capabilities at its Buenos Aires Site
Catalent will add over 11,000 square feet of production space at its Argentinian facility. The expansion has been designed to segregate cytotoxic and highly active products for prescription softgel manufacturing. |
|
|
|
|
|
| |
| |
| Melt Pharmaceuticals Partners with Catalent to Develop its Pain and Sedation Medication Using Zydis® ODT Technology
MELT-100, a patented sublingual, non-opioid pain and sedation medication is being developed in partnership with Catalent using its proprietary Zydis® orally disintegrating tablet (ODT) technology. |
|
|
|
|
|
| |
| Join Our Experts at Live Virtual Events to Hear the Latest on Covid-19 and Technology Development Programs |
|
|
|
|
|
| PEGS Boston | August 31 - September 4 | Virtual Conference
Greg Bleck, Ph.D., Global Head of R&D, Catalent Biologics, will present “GPEx Boost – A Novel Approach for High-Expressing CHO Cell Line Engineering”. Robyn Barfield, Ph.D., Group Leader, Chemical Biology, Catalent Biologics, will also present “Utilizing SMARTag® Bioconjugation Technology to Enable Better-Tolerated Antibody-Drug Conjugates”, as well as her poster, “A Novel HER2-Targeted Antibody-Drug Conjugate Offers the Possibility of Clinical Dosing at Trastuzumab-Equivalent Exposure Levels”.
Webinar | De-risking Orphan Drug Programs in 2020 and Beyond | Sept. 1
Developing therapies for rare diseases has always come with a unique set of challenges. Now, a pandemic has dramatically shifted the attention of the industry and introduced new hurdles - forcing orphan developers into a critical re-examination of their go-to-market strategies. In this webinar, four orphan drug developers will share their learnings.
Webinar | Overcoming Scalability Challenges with Autologous Therapies | September 15 In this webinar, Catalent presents perspectives on scaling autologous therapies from clinical-to-commercial supply. Professor Gerhard Bauer will discuss the current challenges associated with autologous therapies and James Crutchley, Ph.D., will speak to the various solutions available for commercial scale-up of advanced therapeutics.
Webinar | Optimizing Lipid-Based Formulation for Commercial Success | September 15
Register for this 90-minute virtual workshop, BASF & Catalent will demonstrate how lipid-based drug softgel technology can provide formulators with an effective delivery platform in the development and scale-up of commercial products.
Webinar | Exclusive for Pharma Consultants: Strategies to Avoid Dangerous Pitfalls in Pharmaceutical Consulting | September 16
Determining a customer’s primary goal is critical to guiding them through the development of their asset. Learn strategies on how to work with a development partner to avoid costly pitfalls in pharmaceutical consulting and have your questions answered during a live Q&A with former GSK Director of Biopharmaceutics, Alan Parr, Pharm.D., Ph.D. BioCeutics, LLC.
Webinar | Setting Up Your Small Molecule for Success: Formulation, PBPK Modeling and Regulatory Strategies in Early Clinical Trials | September 17
This webinar will focus on the key considerations for transitioning small molecules from preclinical through clinical development. Experts will discuss the technological aspects of drug development and describe practical approaches to improve bioavailability of poorly soluble drugs.
World Vaccine Congress | September 28 - October 1 | Virtual Conference
On Sept.30, George Buchman, Ph.D., Vice President of Preclinical & Process Development, Catalent Cell & Gene Therapy, will present “Next-Generation Vaccines and Oncolytic Viruses: Current Challenges and Future Promise”. |
|
|
|
|
|
| A Catalyst in Drug Development | | Vijay Taladi Senior Scientist, San Diego, California |
|
|
|
|
|
| In his role at Catalent, Vijay specializes in early phase formulation development of new chemical entities (NCEs). He leads a team of chemists and oversees formulation development, scale-up and CGMP manufacturing of compounds using bioavailability enhancing technologies. To learn more, read his published works. |
|
|
| | |
|
|
| |
| |
| |
| |
| |
| |
| |
| Earlier this year, Catalent was certified as a 2020 Top Employer in the United States. Organizations certified as top employers dedicate themselves to providing the very best working environment for employees through their progressive ‘people-first’ HR practices. To learn more about this recognition, click here.
Learn more about careers at Catalent, visit www.catalent.com/careers. |
|
|
| | |
|
|
| |
| Every brand has a challenge. We have a solution. | | | | or call +1 877 891 9609 to speak with one of our experts today! | | |
|
|
|
|
|
| |
| To unsubscribe or manage your subscriptions, please click here.
For more information call +1-866-720-3148 or in Europe 00800 88 55 6178, email us at sales@catalent.com, or visit our website www.catalent.com. And to learn more about Career opportunities across our global network, visit www.catalent.com/careers. Catalent Pharma Solutions respects your privacy. Links to third party sites are provided as a convenience only. Catalent makes no representation or warranty about the technology, security or any content available at these sites. Links are not intended to imply Catalent's affiliation or endorsement of the website, its owner(s) or the content. © 2020, Catalent Pharma Solutions, Inc. 14 Schoolhouse Road, Somerset, NJ 08873. All rights reserved. |
|
|
|
|
|
| |
